



LAHIVE  
&  
COCKFIELD  
L L P

COUNSELLORS AT LAW  
28 STATE STREET  
BOSTON, MASSACHUSETTS 02109-1784  
TELEPHONE (617) 227-7400  
FAX (617) 742-4214  
www.lahive.com

JOHN A. LAHIVE, JR. (1928-1997)  
THOMAS V. SMURZYNSKI  
GIULIO A. DeCONTI, JR.  
ELIZABETH A. HANLEY  
AMY BAKER MANDRAGOURAS  
ANTHONY A. LAURENTANO  
KEVIN J. CANNING  
JANE E. REMILLARD  
DeANN FORAN SMITH  
DEBRA J. MILASINCIC, Ph.D.  
WILLIAM A. SCOFIELD, JR.  
SIBLEY P. REPERT  
DAVID R. BURNS  
JOHN S. CURRAN  
SEAN D. DETWEILER  
MEGAN E. WILLIAMS, Ph.D.  
LISA DIROCCO TYNER  
HATHAWAY P. RUSSELL \*

MARIA LACCOTRIPE ZACHARAKIS, Ph.D.  
MERIDETH C. ARNOLD  
DANIELLE L. HERRITT  
EUIHOON LEE \*\*  
MANEESH GULATI  
CYNTHIA M. SOROOS  
PETER W. DINI, Ph.D.  
MICHAEL J. BASTIAN, Ph.D.  
CHRISTOPHER J. McKENNA

SENIOR COUNSEL  
JAMES E. COCKFIELD

OF COUNSEL  
JEREMIAH LYNCH  
JEANNE M. DIGIORGIO  
CYNTHIA L. KANIK, Ph.D.  
JOHN D. LANZA

PATENT AGENTS  
JONATHAN M. SPARKS, Ph.D.  
ANDRINA WILLIAMS ZINK  
CRISTIN E. HOWLEY, Ph.D.  
JILL ANN MELLO, Ph.D.  
JAMES H. VELEMA \*\*\*

TECHNICAL SPECIALISTS  
CATHERINE M. BISHOP  
JACOB G. WEINTRAUB  
DEBORAH L. NAGLE, Ph.D.  
ANNE JACQUELINE WIZEMAN, Ph.D.  
BRIAN C. TRINQUE, Ph.D.  
CHRISTOPHER R. COWLES, Ph.D.  
W. ELANA WANG

\* Admitted in TX only  
\*\* Admitted in CT only  
\*\*\* Passed Patent Bar Exam

IFW

July 22, 2004

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Re: U.S. Patent Application No.: 10/643768  
For: B-7 DOMAIN-SPECIFIC ANTIBODIES  
Inventors: Sharpe, Arlene H. *et al.*  
Filed: August 18, 2003  
Our Ref. No.: BWI-120CPADV2

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form 1449; and
3. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450:

July 22, 2004  
Date  
DeAnn F. Smith, Esq., Reg. No. 36,683

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP

DeAnn F. Smith, Esq.  
Registration No. 36,683  
Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Sharpe, Arlene H. *et al.*

Serial No.: 10/643768

Filed: August 18, 2003

For: B-7 DOMAIN-SPECIFIC ANTIBODIES

Attorney Docket No.: BWI-120CPADV2

Group Art Unit: 1644

Examiner: Phillip Gambel

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

July 22, 2004

Date of Signature and of Mail Deposit

By:

DeAnn F. Smith, Esq.  
Registration No. 36,683  
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A copy of each cited publication is enclosed.

The present application is a Divisional Application of U.S. Serial No. 09/837,867, filed April 17, 2001, which is a Divisional Application of U.S. Serial No. 08/205,697, filed March 2, 1994, issued as U.S. Patent Number 6,218,510 on April 17, 2001. All references listed on the enclosed PTO Form 1449 have been previously cited by or submitted to the Office in the prior applications, and, in accordance with 37 CFR §1.98(d), copies of these references are not enclosed herewith, but will be provided upon request.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR § 1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP



DeAnn F. Smith, Esq.  
Registration No. 36,683  
Attorney for Applicants

28 State Street  
Boston, MA 02109  
(617) 227-7400

Date: July 22, 2004

AEM/DFS/DLN/alf  
Enclosures



APPLICANT FACSIMILE OF FORM PTO-1449 REV. 7-80		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. <b>BWI-120CPADV2</b>	SERIAL NO. <b>10/643,768</b>
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)				
APPLICANT <b>Sharpe, Arlene H. et al.</b>				
FILING DATE <b>August 18, 2003</b>			GROUP <b>1644</b>	

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	5,942,607	08/99	Freeman <i>et al.</i>	536	23.5	
	A2	6,218,510 B1	04/01	Sharpe <i>et al.</i>	530	350	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	A3	WO 92/00092 A1	01/92	PCT				
	A4	WO 95/03408 A1	02/95	PCT				
	A5	WO 95/06738 A1	03/95	PCT				

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

A6	Augustin, M. <i>et al.</i> 1993. Phorbol-12-Myristate-13-Acetate-treated human keratinocytes express B7-like molecules that serve a costimulatory role in T cell activation. <i>J. Invest. Dermatol.</i> 100(3):275-281		
A7	Azuma, <i>et al.</i> 1993. B70 antigen is a second ligand for CTLA-4 and CD28. <i>Nature</i> , Vol. 366:76-79		
A8	Freedman <i>et al.</i> 1987. B7, a B cell restricted antigen that identifies preactivated b cells. <i>J. Immunol.</i> 139:3260-3267		
A9	Freeman <i>et al.</i> , (1989), "B7, A New Member of the Ig Superfamily With Unique Expression on Activated and Neoplastic B Cells", <i>The Journal of Immunology</i> , Vol. 143, pp. 2714-2722		
A10	Freeman <i>et al.</i> , (1991), "Structure, Expression, and T Cell Costimulatory Activity of the Murine Homologue of the Human B Lymphocyte Activation Antigen B7", <i>Journal of Experimental Medicine</i> , Vol. 174, pp. 625-631		
A11	Freeman <i>et al.</i> , (1993), "Murine B7-2, an Alternative CTLA4 Counter-receptor that Costimulates T Cell Proliferation and Interleukin 2 Production", <i>The Journal of Experimental Medicine</i> , Vol. 178, pp. 2185-2192		
A12	Freeman <i>et al.</i> , (1993), "Uncovering of Functional Alternative CTLA-4 Counter-Receptor in B7-Deficient Mice", <i>Science</i> , Vol. 262, pp. 907-909.		
A13	Freeman, G.J. <i>et al.</i> "Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation," <i>Science</i> 262:909-911 (1993)		
A14	Freeman <i>et al.</i> 1992. The gene for B7, a costimulatory signal for T cell activation, maps to chromosomal region 3q13.3-3q21. <i>Blood</i> . 79:489-494		
A15	Gimmi <i>et al.</i> 1991. B cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. <i>PNAS</i> 88:6575-6579		
A16	Harding <i>et al.</i> 1992. CD28-mediated signaling costimulates murine T cells and prevents induction of anergy in T cell clones. <i>Nature</i> 356:607-609		
A17	Hathcock <i>et al.</i> 1993. Identification of an alternative CTLA4 ligand costimulatory for T cell activation. <i>Science</i> . 262:905-907		
Examiner		Date Considered	
*EXAMINER:		Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

